menu
    • menu

    Find Trametinib manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 21
    Polpharma Trametinib

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    23

    API Suppliers

    6

    USDMF

    0

    CEP/COS

    0

    JDMF

    2

    EU WC

    1

    KDMF

    7

    NDC API

    0

    VMF

    16

    Listed Suppliers

    13INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    47

    FDF Dossiers

    8

    FDA Orange Book

    20

    Europe

    3

    Canada

    14

    Australia

    2

    South Africa

    0

    Listed Dossiers

    21PROSPECTS

    65DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    175RELATED EXCIPIENT COMPANIES

    297EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    87

    US Patents

    34

    US Exclusivities

    10

    Health Canada Patents
    API/FDF Prices: Book a Demo

    API REF. PRICE (USD/KG)

    $
    $ 472,738

    GLOBAL SALES INFORMATION

    US Medicaid

    173,398,802

    Annual Reports

    19,168

    Regulatory FDF Prices

    NA

    MARKET PLACE

    3

    API

    0

    FDF

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    49

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 871700-17-3, Gsk1120212, Mekinist, Gsk-1120212, Jtp 74057, Jtp-74057
    Molecular Formula
    C26H23FIN5O4
    Molecular Weight
    615.4  g/mol
    InChI Key
    LIRYPHYGHXZJBZ-UHFFFAOYSA-N
    FDA UNII
    33E86K87QN
    Trametinib
    Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.
    Trametinib is a Kinase Inhibitor. The mechanism of action of trametinib is as a Protein Kinase Inhibitor.
    1 2D Structure

    Trametinib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
    2.1.2 InChI
    InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
    2.1.3 InChI Key
    LIRYPHYGHXZJBZ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
    2.2 Other Identifiers
    2.2.1 UNII
    33E86K87QN
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Gsk 1120212

    2. Gsk-1120212

    3. Gsk1120212

    4. Jtp 74057

    5. Jtp-74057

    6. Jtp74057

    2.3.2 Depositor-Supplied Synonyms

    1. 871700-17-3

    2. Gsk1120212

    3. Mekinist

    4. Gsk-1120212

    5. Jtp 74057

    6. Jtp-74057

    7. Gsk 1120212

    8. Trametinib (gsk1120212)

    9. N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide

    10. Gsk212

    11. Tmt212

    12. Trametinib [usan]

    13. Chebi:75998

    14. Tmt-212

    15. 33e86k87qn

    16. Trametinib (usan)

    17. N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl}phenyl)acetamide

    18. N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide

    19. Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- Dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2h)-yl)phenyl)-

    20. N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl)phenyl)acetamide

    21. Unii-33e86k87qn

    22. Trametinib [usan:inn]

    23. Trametinibum

    24. Jtp74057

    25. N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- Tetrahydropyrido(4,3-d)pyrimidin-1(2h)-yl)phenyl)acetamide

    26. N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido(4,3-d)pyrimidin-1(2h)-yl)phenyl)acetamide

    27. N-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- Tetrahydropyrido(4,3-d)pyrimidin-1(2h)-yl}phenyl)acetamide

    28. Qom

    29. Trametinib [mi]

    30. Trametinib (gsk1120212jtp 74057)

    31. Trametinib [inn]

    32. Trametinib [vandf]

    33. Trametinib [who-dd]

    34. Schembl170938

    35. Gtpl6495

    36. Gsk1120212 (trametinib)

    37. Chembl2103875

    38. Ex-a022

    39. Bcpp000218

    40. Dtxsid901007381

    41. Hms3295i05

    42. Hms3656j11

    43. Bcp02307

    44. Bdbm50531540

    45. Mfcd17215075

    46. Nsc758246

    47. Nsc800956

    48. S2673

    49. Zinc43100709

    50. Akos015850628

    51. Am90271

    52. Ccg-264976

    53. Cs-0060

    54. Db08911

    55. Ex-5957

    56. Nsc-758246

    57. Nsc-800956

    58. Sb16553

    59. Ncgc00263180-01

    60. Ncgc00263180-07

    61. Ncgc00263180-14

    62. Ac-25891

    63. As-19382

    64. Hy-10999

    65. N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide

    66. Ft-0688438

    67. Sw218089-2

    68. A25168

    69. D10175

    70. Gsk1120212 - Jtp-74057

    71. Gsk1120212,jtp-74057, Gsk212

    72. Sr-01000941589

    73. A1-01871

    74. J-523325

    75. Q7833138

    76. Sr-01000941589-1

    77. Brd-k12343256-001-01-4

    78. Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]-

    79. N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl)phenyl)acetamide

    80. N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phe Nyl]acetamide

    81. N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide

    82. N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl}ethanimidic Acid

    83. N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 615.4 g/mol
    Molecular Formula C26H23FIN5O4
    XLogP33.4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count5
    Exact Mass615.07788 g/mol
    Monoisotopic Mass615.07788 g/mol
    Topological Polar Surface Area102 Ų
    Heavy Atom Count37
    Formal Charge0
    Complexity1090
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameMekinist
    PubMed HealthTrametinib (By mouth)
    Drug ClassesAntineoplastic Agent
    Drug LabelTrametinib dimethyl sulfoxide is a kinase inhibitor. The chemical name is acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4- iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl- 2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-, compound with 1,1-sul...
    Active IngredientTrametinib dimethyl sulfoxide
    Dosage FormTablet
    RouteOral
    Strengtheq 1mg non-solvated parent; eq 0.5mg non-solvated parent; eq 2mg non-solvated parent
    Market StatusPrescription
    CompanyGlaxosmithkline

    2 of 2  
    Drug NameMekinist
    PubMed HealthTrametinib (By mouth)
    Drug ClassesAntineoplastic Agent
    Drug LabelTrametinib dimethyl sulfoxide is a kinase inhibitor. The chemical name is acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4- iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl- 2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-, compound with 1,1-sul...
    Active IngredientTrametinib dimethyl sulfoxide
    Dosage FormTablet
    RouteOral
    Strengtheq 1mg non-solvated parent; eq 0.5mg non-solvated parent; eq 2mg non-solvated parent
    Market StatusPrescription
    CompanyGlaxosmithkline

    4.2 Drug Indication

    Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test [FDA]. In May 2018, it was approved for use with [DB08912] for the treatment of treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.

    FDA Label

    * Melanoma:

    Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4. 4 and 5. 1).

    Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5. 1).

    * Adjuvant treatment of melanoma:

    Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

    * Non-small cell lung cancer (NSCLC):

    Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Trametinib is an anticancer agent which causes apoptosis (or programmed cell death) and inhibits cell proliferation, which are both important in the treatment of malignancies.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    TRAMETINIB
    5.3.2 FDA UNII
    33E86K87QN
    5.3.3 Pharmacological Classes
    Protein Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]
    5.4 ATC Code

    L01EE01

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01E - Protein kinase inhibitors

    L01EE - Mitogen-activated protein kinase (mek) inhibitors

    L01EE01 - Trametinib

    5.5 Absorption, Distribution and Excretion

    Absorption

    Trametinib is readily absorbed. When an oral administration of trametinib was given to patients with BRAF V600 mutation-positive melanoma, peak plasma concentration occurred 1.5 hours post-dose (Tmax). A single 2 mg oral dose has a bioavailability of 72%. When a dose of 2mg/day is given, the peak plasma concentration (Cmax) is 22.2 ng/mL.

    Route of Elimination

    80% of the dose is excreted in the feces. <20% of the dose is excreted in the urine with <0.1% of the excreted dose in the form of the parent compound.

    Volume of Distribution

    Apparent volume of distribution (Vd/F) = 214 L

    Clearance

    Apparent clearance = 4.9 L/h

    5.6 Metabolism/Metabolites

    Trametinib is metabolized predominantly via deacetylation alone or with mono-oxygenation or in combination with glucuronidation biotransformation pathways in vitro. Deacetylation is likely mediated by hydrolytic enzymes, such as carboxyl-esterases or amidases. The cytochrome P450 enzyme system is not involved with the metabolism of trametinib. The predominant circulating component in the plasma is the parent drug.

    5.7 Biological Half-Life

    Elimination half-life = 3.9-4.8 days.

    5.8 Mechanism of Action

    Trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 _(MEK1)_ and _MEK2_ activation and of_ MEK1_ and _MEK2_ kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. Trametinib helps with melanoma with the BRAF V600E or V600K as the mutation results in the constitutive activation of the BRAF pathway which includes MEK1 and MEK2.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655231400,"product":"TRAMETINIB DMSO","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"KUALA LUMPUR - INT\\'L","customer":"ONCOGEN PHARMA MALAYSIA SDN BHD","customerCountry":"MALAYSIA","quantity":"0.08","actualQuantity":"0.075","unit":"KGS","unitRateFc":"500000","totalValueFC":"36838.9","currency":"USD","unitRateINR":38320000,"date":"15-Jun-2022","totalValueINR":"2874000","totalValueInUsd":"36838.9","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"2132848","productDescription":"API","marketType":"","country":"MALAYSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702837800,"product":"TRAMETINIB DIMETHYL SULFOXIDE(FORM-M)(QTY:0.030 KGS)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"UNDISCLOSED","customerCountry":"ISRAEL","quantity":"0.03","actualQuantity":"0.03","unit":"KGS","unitRateFc":"500000","totalValueFC":"14872.1","currency":"USD","unitRateINR":41266666.666666672,"date":"18-Dec-2023","totalValueINR":"1238000","totalValueInUsd":"14872.1","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"6124421","productDescription":"API","marketType":"","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734546600,"product":"TRAMETINIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"SUNNY PHARMATECH INC","customerCountry":"TAIWAN","quantity":"0.02","actualQuantity":"0.015","unit":"KGS","unitRateFc":"448890.9","totalValueFC":"6648.7","currency":"USD","unitRateINR":37661950,"date":"19-Dec-2024","totalValueINR":"564929.25","totalValueInUsd":"6648.7","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"6578642","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1743964200,"product":"TRAMETINIB DIMETHYL SULFOXIDE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MALTA","customer":"PHARMACARE PREMIUM LTD","customerCountry":"MALTA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"653750","totalValueFC":"128934.2","currency":"USD","unitRateINR":55185000,"date":"07-Apr-2025","totalValueINR":"11037000","totalValueInUsd":"128934.2","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"9757427","productDescription":"API","marketType":"REGULATED MARKET","country":"MALTA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1754073000,"product":"TRAMETINIB DIMETHYL SULFOXIDE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"JSC BIOKHIMIK","customerCountry":"RUSSIA","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"21500000","totalValueFC":"36538.9","currency":"INR","unitRateINR":21319127.800000001,"date":"02-Aug-2025","totalValueINR":"3197869.17","totalValueInUsd":"36538.9","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4127426","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1758479400,"product":"TRAMETINIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"SUNNY PHARMATECH INC","customerCountry":"TAIWAN","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"450","totalValueFC":"8817.4","currency":"USD","unitRateINR":38915.25,"date":"22-Sep-2025","totalValueINR":"778305","totalValueInUsd":"8817.4","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"5523510","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1754073000,"product":"TRAMETINIB BATCH NO - VTM0040824 TRAMETINIB BATCH NO - VTM0040824","address":"705, Kailash Corporate Lounge, Vikhroli, ,? Hiranandani Link Road, , ,? Vikhroli W , ?MUMBAI ,? MAHARASHTRA,? 400076","city":"","supplier":"LOTUS PHARMACEUTICAL CO LTD","supplierCountry":"TAIWAN","foreign_port":"TAIPEI","customer":"MEISHI PHARMA SERVICES PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.09","actualQuantity":"0.09","unit":"KGS","unitRateFc":"610834.4","totalValueFC":"54523","currency":"USD","unitRateINR":"53020429.3","date":"02-Aug-2025","totalValueINR":"4771838.64","totalValueInUsd":"54523","indian_port":"Hyderabad Air","hs_no":"29222990","bill_no":"3648017","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"TAIPEI","supplierAddress":"NO.30 CHENGGONG 1ST RD SINSING VILLAGE NANTOU CITY NANTOU COUNTY 540 TAIWAN TAIWAN","customerAddress":"705, Kailash Corporate Lounge, Vikhroli, ,? Hiranandani Link Road, , ,? Vikhroli W , ?MUMBAI ,? MAHARASHTRA,? 400076"}]
    15-Jun-2022
    22-Sep-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Hikma acquires Novugen's FDA-approved ANDA for trametinib

    Details:

    Through the acquisition, Hikma holds the rights of Mekinist-Generic (trametinib dimethyl sulfoxide) tablets from Novugen. It is being indicated for the treatment of BRAF-mutated melanoma.


    Lead Product(s): Trametinib,Inapplicable

    Therapeutic Area: Oncology Brand Name: Mekinist-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Hikma Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition April 17, 2025

    blank

    01

    Novugen

    U.A.E
    arrow
    SCOPE Summit
    Not Confirmed

    Novugen

    U.A.E
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trametinib,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Hikma Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Hikma acquires Novugen's FDA-approved ANDA for trametinib

    Details : Through the acquisition, Hikma holds the rights of Mekinist-Generic (trametinib dimethyl sulfoxide) tablets from Novugen. It is being indicated for the treatment of BRAF-mutated melanoma.

    Product Name : Mekinist-Generic

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    April 17, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

    Details:

    Trametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Histiocytosis, Langerhans-Cell.


    Lead Product(s): Trametinib,Inapplicable

    Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 03, 2024

    blank

    02

    Cook Children's Health Care System

    Country
    arrow
    SCOPE Summit
    Not Confirmed

    Cook Children's Health Care System

    Country
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trametinib,Inapplicable

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

    Details : Trametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Histiocytosis, Langerhans-Cell.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    September 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Erasca Starts Phase 3 Trial for Naporafenib in Melanoma

    Details:

    ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.


    Lead Product(s): Naporafenib,Trametinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 18, 2024

    blank

    03

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naporafenib,Trametinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Erasca Starts Phase 3 Trial for Naporafenib in Melanoma

    Details : ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    June 18, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

    Details:

    Trametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.


    Lead Product(s): Trametinib,Anlotinib Hydrochloride,Tislelizumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Sponsor: BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 13, 2024

    blank

    04

    Shanghai Chest Hospital

    Country
    arrow
    SCOPE Summit
    Not Confirmed

    Shanghai Chest Hospital

    Country
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trametinib,Anlotinib Hydrochloride,Tislelizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

    Details : Trametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    June 13, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Erasca Announces Closing of Underwritten Offering of Common Stock and Additional Shares

    Details:

    The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.


    Lead Product(s): Naporafenib,Trametinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: J.P. Morgan

    Deal Size: $184.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering May 21, 2024

    blank

    05

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naporafenib,Trametinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : J.P. Morgan

    Deal Size : $184.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Erasca Announces Closing of Underwritten Offering of Common Stock and Additional Shares

    Details : The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    May 21, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

    Details:

    Naporafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Melanoma.


    Lead Product(s): Naporafenib,Trametinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 03, 2024

    blank

    06

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naporafenib,Trametinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant...

    Details : Naporafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Melanoma.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Erasca Announces $45 Million Oversubscribed Private Placement Financing

    Details:

    Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.


    Lead Product(s): Naporafenib,Trametinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: BofA Securities

    Deal Size: $45.0 million Upfront Cash: Undisclosed

    Deal Type: Private Placement March 27, 2024

    blank

    07

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naporafenib,Trametinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : BofA Securities

    Deal Size : $45.0 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Erasca Announces $45 Million Oversubscribed Private Placement Financing

    Details : Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    March 27, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Erasca Announces Clinical Trial Collaboration and Supply Agreements for Trametinib

    Details:

    The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.


    Lead Product(s): Naporafenib,Trametinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Novartis Pharmaceuticals Corporation

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 14, 2024

    blank

    08

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naporafenib,Trametinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Erasca Announces Clinical Trial Collaboration and Supply Agreements for Trametinib

    Details : The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    February 14, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

    Details:

    LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .


    Lead Product(s): Naporafenib,Trametinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 11, 2023

    blank

    09

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed

    Erasca

    U.S.A
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Naporafenib,Trametinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advan...

    Details : LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    December 11, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

    Details:

    Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thyroid Carcinoma, Anaplastic.


    Lead Product(s): Dabrafenib Mesylate,Trametinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Novartis Pharmaceuticals Corporation

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 12, 2023

    blank

    10

    Leiden University Medical Center

    Country
    arrow
    SCOPE Summit
    Not Confirmed

    Leiden University Medical Center

    Country
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dabrafenib Mesylate,Trametinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Stu...

    Details : Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thyroid Carcinoma, Anaplastic.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 12, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    INTERMEDIATE SUPPLIERS

    read-more
    read-more

    01

    Ami Organics Private Limited

    India
    SCOPE Summit
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    3-CYCLOPROPYL-1-(2-FLUORO-4-IODOPHENYL)-6 (METHYLA...

    CAS Number : 871700-22-0

    End Use API : Trametinib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Ami Organics Private Limited

    India
    SCOPE Summit
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    6-AMINO-3-CYCLOPROPYL-1-(2-FLUORO-4-IODOPHENYL) P...

    CAS Number : 871700-28-6

    End Use API : Trametinib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    N-(3-(3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-...

    CAS Number : 871700-25-3

    End Use API : Trametinib

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6,8-dimeth...

    CAS Number : 871700-32-2

    End Use API : Trametinib

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-5-hydroxy-...

    CAS Number : 871700-24-2

    End Use API : Trametinib

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6-(methyla...

    CAS Number : 871700-22-0

    End Use API : Trametinib

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    (E)-N'-(1-cyclopropyl-3-(2-fluoro-4 -iodophenyl)-2...

    CAS Number : 871700-30-0

    End Use API : Trametinib

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    6-amino-3-cyclopropyl-1-(2-fluoro-4-iodophenyl)pyr...

    CAS Number : 871700-28-6

    End Use API : Trametinib

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow

    Guangdong Raffles PharmaTech Co Ltd

    China
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    1-cyclopropyl-3-(2-fluoro-4-iodophenyl)urea

    CAS Number : 871700-18-4

    End Use API : Trametinib

    About The Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceu...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Hangzhou Longshine Bio-Tech Co.,LTD

    China
    SCOPE Summit
    Not Confirmed
    arrow

    Hangzhou Longshine Bio-Tech Co.,LTD

    China
    SCOPE Summit
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6-(methyla...

    CAS Number : 871700-22-0

    End Use API : Trametinib

    About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Hikma Pharmaceuticals

    United Kingdom
    SCOPE Summit
    Not Confirmed
    arrow

    Hikma Pharmaceuticals

    United Kingdom
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : DISCN

    Registration Country : USA

    TRAMETINIB DIMETHYL SULFOXIDE

    Brand Name : TRAMETINIB DIMETHYL SULFOXIDE

    Dosage Form : TABLET;ORAL

    Dosage Strength : EQ 0.5MG

    Packaging :

    Approval Date : 2024-08-06

    Application Number : 219002

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Hikma Pharmaceuticals

    United Kingdom
    SCOPE Summit
    Not Confirmed
    arrow

    Hikma Pharmaceuticals

    United Kingdom
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : DISCN

    Registration Country : USA

    TRAMETINIB DIMETHYL SULFOXIDE

    Brand Name : TRAMETINIB DIMETHYL SULFOXIDE

    Dosage Form : TABLET;ORAL

    Dosage Strength : EQ 2MG

    Packaging :

    Approval Date : 2024-08-06

    Application Number : 219002

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    SCOPE Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    TRAMETINIB DIMETHYL SULFOXIDE

    Brand Name : MEKINIST

    Dosage Form : TABLET;ORAL

    Dosage Strength : EQ 0.5MG

    Packaging :

    Approval Date : 2013-05-29

    Application Number : 204114

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    SCOPE Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : DISCN

    Registration Country : USA

    TRAMETINIB DIMETHYL SULFOXIDE

    Brand Name : MEKINIST

    Dosage Form : TABLET;ORAL

    Dosage Strength : EQ 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    Packaging :

    Approval Date : 2013-05-29

    Application Number : 204114

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    SCOPE Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    TRAMETINIB DIMETHYL SULFOXIDE

    Brand Name : MEKINIST

    Dosage Form : TABLET;ORAL

    Dosage Strength : EQ 2MG

    Packaging :

    Approval Date : 2013-05-29

    Application Number : 204114

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    SCOPE Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    TRAMETINIB DIMETHYL SULFOXIDE

    Brand Name : MEKINIST

    Dosage Form : SOLUTION;ORAL

    Dosage Strength : EQ 0.05MG BASE/ML

    Packaging :

    Approval Date : 2023-03-16

    Application Number : 217513

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    SCOPE Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : USA

    TRAMETINIB

    Brand Name : MEKINIST

    Dosage Form : TABLET;ORAL

    Dosage Strength : 2MG

    Packaging :

    Approval Date :

    Application Number : 217513

    Regulatory Info :

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    SCOPE Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : USA

    TRAMETINIB

    Brand Name : MEKINIST

    Dosage Form : SOLUTION;ORAL

    Dosage Strength : 4.7MG

    Packaging :

    Approval Date :

    Application Number : 217513

    Regulatory Info :

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    SCOPE Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Approved

    Registration Country : Sweden

    Trametinib Dimethyl Sulfoxide

    Brand Name : Mekinist

    Dosage Form : Film Coated Tablet

    Dosage Strength : 0.5mg

    Packaging :

    Approval Date : 30/06/2014

    Application Number : 20130212000025

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    SCOPE Summit
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    SCOPE Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Approved

    Registration Country : Sweden

    Trametinib Dimethyl Sulfoxide

    Brand Name : Mekinist

    Dosage Form : Film Coated Tablet

    Dosage Strength : 2mg

    Packaging :

    Approval Date : 30/06/2014

    Application Number : 20130212000056

    Regulatory Info : Approved

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - EQ 0.5MG

    USFDA APPLICATION NUMBER - 204114

    read-more

    DOSAGE - TABLET;ORAL - EQ 1MG **Federal Regis...DOSAGE - TABLET;ORAL - EQ 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 204114

    read-more

    DOSAGE - TABLET;ORAL - EQ 2MG

    USFDA APPLICATION NUMBER - 204114

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Topical

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for 871700-17-3 / Trametinib API manufacturers, exporters & distributors?

    Trametinib manufacturers, exporters & distributors 1

    71

    PharmaCompass offers a list of Trametinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Trametinib manufacturer or Trametinib supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Trametinib manufacturer or Trametinib supplier.

    PharmaCompass also assists you with knowing the Trametinib API Price utilized in the formulation of products. Trametinib API Price is not always fixed or binding as the Trametinib Price is obtained through a variety of data sources. The Trametinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Trametinib

    Synonyms

    871700-17-3, Gsk1120212, Mekinist, Gsk-1120212, Jtp 74057, Jtp-74057

    Cas Number

    871700-17-3

    Unique Ingredient Identifier (UNII)

    33E86K87QN

    About Trametinib

    Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.

    Trametinib Dimethyl Sulfoxide Manufacturers

    A Trametinib Dimethyl Sulfoxide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trametinib Dimethyl Sulfoxide, including repackagers and relabelers. The FDA regulates Trametinib Dimethyl Sulfoxide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trametinib Dimethyl Sulfoxide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Trametinib Dimethyl Sulfoxide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Trametinib Dimethyl Sulfoxide Suppliers

    A Trametinib Dimethyl Sulfoxide supplier is an individual or a company that provides Trametinib Dimethyl Sulfoxide active pharmaceutical ingredient (API) or Trametinib Dimethyl Sulfoxide finished formulations upon request. The Trametinib Dimethyl Sulfoxide suppliers may include Trametinib Dimethyl Sulfoxide API manufacturers, exporters, distributors and traders.

    click here to find a list of Trametinib Dimethyl Sulfoxide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Trametinib Dimethyl Sulfoxide USDMF

    A Trametinib Dimethyl Sulfoxide DMF (Drug Master File) is a document detailing the whole manufacturing process of Trametinib Dimethyl Sulfoxide active pharmaceutical ingredient (API) in detail. Different forms of Trametinib Dimethyl Sulfoxide DMFs exist exist since differing nations have different regulations, such as Trametinib Dimethyl Sulfoxide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Trametinib Dimethyl Sulfoxide DMF submitted to regulatory agencies in the US is known as a USDMF. Trametinib Dimethyl Sulfoxide USDMF includes data on Trametinib Dimethyl Sulfoxide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Trametinib Dimethyl Sulfoxide USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Trametinib Dimethyl Sulfoxide suppliers with USDMF on PharmaCompass.

    Trametinib Dimethyl Sulfoxide KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Trametinib Dimethyl Sulfoxide Drug Master File in Korea (Trametinib Dimethyl Sulfoxide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Trametinib Dimethyl Sulfoxide. The MFDS reviews the Trametinib Dimethyl Sulfoxide KDMF as part of the drug registration process and uses the information provided in the Trametinib Dimethyl Sulfoxide KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Trametinib Dimethyl Sulfoxide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Trametinib Dimethyl Sulfoxide API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Trametinib Dimethyl Sulfoxide suppliers with KDMF on PharmaCompass.

    Trametinib Dimethyl Sulfoxide WC

    A Trametinib Dimethyl Sulfoxide written confirmation (Trametinib Dimethyl Sulfoxide WC) is an official document issued by a regulatory agency to a Trametinib Dimethyl Sulfoxide manufacturer, verifying that the manufacturing facility of a Trametinib Dimethyl Sulfoxide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Trametinib Dimethyl Sulfoxide APIs or Trametinib Dimethyl Sulfoxide finished pharmaceutical products to another nation, regulatory agencies frequently require a Trametinib Dimethyl Sulfoxide WC (written confirmation) as part of the regulatory process.

    click here to find a list of Trametinib Dimethyl Sulfoxide suppliers with Written Confirmation (WC) on PharmaCompass.

    Trametinib Dimethyl Sulfoxide NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Trametinib Dimethyl Sulfoxide as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Trametinib Dimethyl Sulfoxide API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Trametinib Dimethyl Sulfoxide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Trametinib Dimethyl Sulfoxide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Trametinib Dimethyl Sulfoxide NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Trametinib Dimethyl Sulfoxide suppliers with NDC on PharmaCompass.

    Trametinib Dimethyl Sulfoxide GMP

    Trametinib Dimethyl Sulfoxide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Trametinib Dimethyl Sulfoxide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trametinib Dimethyl Sulfoxide GMP manufacturer or Trametinib Dimethyl Sulfoxide GMP API supplier for your needs.

    Trametinib Dimethyl Sulfoxide CoA

    A Trametinib Dimethyl Sulfoxide CoA (Certificate of Analysis) is a formal document that attests to Trametinib Dimethyl Sulfoxide's compliance with Trametinib Dimethyl Sulfoxide specifications and serves as a tool for batch-level quality control.

    Trametinib Dimethyl Sulfoxide CoA mostly includes findings from lab analyses of a specific batch. For each Trametinib Dimethyl Sulfoxide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Trametinib Dimethyl Sulfoxide may be tested according to a variety of international standards, such as European Pharmacopoeia (Trametinib Dimethyl Sulfoxide EP), Trametinib Dimethyl Sulfoxide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trametinib Dimethyl Sulfoxide USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search